Preclinical pharmacokinetic PET studies with radiolabeled potential new drugs in man

Drug Information Journal

Volumn 31, Issue 3, 1997, Pages 1015-1018

  Vaalburg, Willem ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Drug development; Positron emission tomography; Preclinical

Indexed keywords

4 (3 TERT BUTYLAMINO 2 HYDROXYPROPOXY) 2 BENZIMIDAZOLONE; BETA ADRENERGIC RECEPTOR; CARAZOLOL; CARBON 11; CYANOPINDOLOL I 125; FLUORINE; FLUORINE 18; FLUOROCARAZOLOL; HYDROGEN; IODOPINDOLOL I 125; LIGAND; NITROGEN 13; OXYGEN 15; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; TRITIUM; UNCLASSIFIED DRUG;

ARTICLE; AUTORADIOGRAPHY; CYCLOTRON; DRUG DEVELOPMENT; DRUG DISTRIBUTION; FOOD AND DRUG ADMINISTRATION; GOOD MANUFACTURING PRACTICE; HALF LIFE TIME; HUMAN; ISOTOPE LABELING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; TOXICITY;

EID: 0030749734     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286159703100345     Document Type: Article

References (4)

1. Federal Register. 1995;60:10593-10596.
2. European Pharmacopoeia. 1987; v.2.1.5. Abnormal toxicity.
3. 18F]Fluorocarazolol, ligands for the visualization of pulmonary β-adrenergic receptors with PET. Nucl Med Biol. 1995;23:159-167.
4. van Waarde A, Visser TJ, Elsinga PH, Pruim J, van de Mark ThW, Kraan J, Ensing K, de Jong BM, Jansen T, Visser GM, Paans AMJ. Vaalburg W. First delineation of β-adrenoceptors in the human brain using fluorocarazolol-PET. J Nucl Med. 1996;37:11P.